Hayden E. Klein

In his explanation of the tremelimumab priming dose, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, also reviews and analogizes checkpoint inhibitors as a whole.

Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Coverage of ASCO sessions and posters that addressed lessons from the Oncology Care Model and concerns about the Enhancing Oncology Model, which launched shortly after the annual meeting ended.

Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, expands on findings that durvalumab plus tremelimumab demonstrated an overall survival benefit at 4 years for certain patients with unresectable hepatocellular carcinoma.

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

Among people living with HIV receiving antiretroviral therapy, those taking 4-mg pitavastatin daily were 35% less likely than those taking placebo to experience a major cardiovascular event over 5 years of follow-up.

New research suggests that when cancer cells are under stress, cellular chaperone protein GRP78 alters its behavior and migrates to the cell's nucleus, where it modifies gene activities and allows cancer cells to become more mobile and invasive.

After replicating the PURE study, researchers found that individuals with higher PURE diet scores had lower risk of death, cardiovascular disease, myocardial infarction, and stroke.

The biggest barriers in collaboration are communication and connectivity, said Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology.

While the overall age-adjusted mortality rate for diabetes and cardiovascular disease (CVD) declined between 1999 and 2019, researchers found an average annual 1% increase since 2014.

Among 172 patients with untreated advanced solid tumors, all of them had actionable alterations, and 109 had druggable alterations.

Research suggests that intense physical activity concentrated within 1-2 days and activity more evenly distributed activity across several days are associated with similarly lower risk of cardiovascular outcomes.

According to a Kaiser Family Foundation analysis, 22% of Medicare Part D drug spending in 2021 went towards the 10 top-selling prescription drugs alone.

Sydney Townsend, executive director of digital health at Texas Oncology, explains how cancer diagnosis and treatment can impact a patient’s mental well-being and how she assesses a patient’s overall cancer care experience.

Between 1999 and 2020, rates of liver cancer deaths increased for Hispanic men and women, and pancreas and uterine cancer deaths have increased for Hispanic women.

Research was conducted by multiple laboratories in the Global Diagnostics Network and included more than 460 million lipid test results from 17 countries to determine risk of cardiovascular disease (CVD).

After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.

Once-daily venous thromboembolism (VTE) prophylaxis with 10 mg of rivaroxaban for either 7 or 28 days after bariatric surgery was found to be effective and safe.

There may be significant differences in kidney disease between individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D).

Adam Colborn, JD, director of government relations at the Academy of Managed Care Pharmacy (AMCP), also explains what health systems can do to improve patient access to biosimilars.

Type 1 diabetes incidence was 1.14 times higher in the first year and 1.27 times higher in the second year of the COVID-19 pandemic, compared with the 12 months before the pandemic.

Interpersonal support, residing in a rural area, and not disclosing HIV status to partners were all found to be linked to higher antiretroviral therapy (ART) adherence, all at different degrees.

Andrew Bolibol, a PhD candidate in Harvard University’s Health Policy Program, highlights trends and gaps in health insurance coverage between LGBT and non-LGBT adults.

The American Diabetes Association (ADA) announced updates to multiple sections of its Standards of Care in Diabetes–2023, as announced at the ADA 83rd Scientific Sessions.

Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains how education can help with biosimilar adoption and how an updated biosimilar workflow has simplified the prior authorization process.

Late-breaking results of the COORDINATE-Diabetes trial were presented today at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, California.

New findings show that VX-880, a stem cell-derived islet cell therapy, can restore endogenous insulin secretion and improve glycemic control in people living with type 1 diabetes (T1D).

New estimates predict that type 2 diabetes prevalence will more than double in the next 30 years, from 529 million people in 2021 to at least 1.3 billion in 2050.